The information highlighted (if any) are the most recent updates for this brand.
Cervarix is indicated in females from 9 through 25 years of age for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous cell carcinoma and adenocarcinoma) caused by oncogenic Human Papillomavirus (HPV) types 16, and 18 (see Pharmacology: Pharmacodynamics under Actions and Precautions for more information on HPV 16, 18 and other oncogenic types).